Anabolic steroid guide
Anabolic-Androgenic Steroid

Masteron

Masteron is the brand name for drostanolone, a synthetic dihydrotestosterone (DHT)–derived androgen historically used in oncology and encountered today mainly as an anabolic-androgenic steroid used non-medically. Clinical data are limited and risks are well documented.

Drostanolone
Drostanolone enanthate
Drostanolone propionate
Masteron Depot
Permastril

This guide covers all common forms and variations of masteron in one place. Use the sections below to find the form that fits your situation.

How it works in the body

Drostanolone is a synthetic DHT derivative that acts as an androgen receptor agonist. Binding to androgen receptors in skeletal muscle and other tissues promotes protein synthesis and nitrogen retention, producing anabolic effects.

Unlike testosterone, drostanolone cannot be converted to estradiol by aromatase (it is non-aromatizable), which reduces estrogenic side effects such as gynecomastia. However, it still suppresses the HPT axis through androgen-mediated negative feedback, reducing endogenous testosterone production. Additional effects include adverse changes to lipid metabolism, stimulation of erythropoiesis (raising hematocrit), and androgen receptor–mediated effects in the central nervous system.

Drostanolone molecular structure
2D molecular structure from PubChem, National Library of Medicine.

Body systems

Endocrine system
Musculoskeletal system
Cardiovascular system
Reproductive system

Associated molecules

Drostanolone (DHT derivative)
Androgen receptor agonist

Track it lightly

If you are monitoring health while exposed to this compound, record objective lab values and symptoms regularly. Sharing that data with a clinician improves safety management.

Trying this? Start tracking it here.

Background

Drostanolone was developed in the mid-20th century and marketed under brand names including Masteron and Permastril. It was investigated for hormone-responsive advanced breast cancer on the basis that androgenic activity could antagonize estrogen-driven tumor growth. Its medical use declined as selective estrogen receptor modulators, aromatase inhibitors, and other targeted therapies became standard of care. Drostanolone is now encountered primarily in non-medical performance and physique contexts. It is a controlled substance in many countries and is included on WADA's prohibited list, meaning possession and use without a prescription carry legal and sporting-eligibility consequences.

Evidence snapshot

Drostanolone is a synthetic androgen derived from dihydrotestosterone. Medical literature on it is limited and mostly historical: it was studied for hormone-responsive breast cancer therapy, but modern oncology rarely uses it given the availability of superior endocrine agents. No contemporary high-quality randomized trials exist for approved indications.

Most current evidence on Masteron derives from the broader anabolic-androgenic steroid (AAS) literature, which documents short-term anabolic effects alongside consistent harms: suppression of endogenous testosterone production, adverse lipid changes, cardiovascular effects, psychiatric effects, and androgenic side effects. This evidence base consists primarily of observational studies, cohort analyses, case reports, and reviews rather than drostanolone-specific controlled trials.

Because drostanolone is non-aromatizable, it does not convert to estrogen, which lowers the risk of estrogenic gynecomastia compared with aromatizable androgens. This does not eliminate cardiovascular, reproductive, or psychiatric risks. Legal status and product quality control are additional practical concerns outside medical supervision.

Bioavailability & pharmacokinetics

Drostanolone is formulated as an intramuscular ester to prolong systemic exposure. The propionate ester has a shorter half-life (approximately 1–2 days), requiring injections every other day to maintain stable blood levels. The enanthate ester is longer-acting and supports once- or twice-weekly dosing. As a DHT derivative, drostanolone has high androgen receptor affinity and is metabolized in peripheral tissues and the liver. Because it is non-aromatizable, it does not raise estradiol through aromatase conversion.

Populations studied

Randomized controlled trials of drostanolone for contemporary medical indications are absent. Historical oncology literature examined androgen therapy — including drostanolone — in postmenopausal women with advanced breast cancer; those studies are limited by small sample sizes, lack of modern comparators, and dated methodology. Contemporary safety and pharmacology data are drawn from AAS-user cohort studies and aggregate reviews, not drostanolone-specific trials.

Long-term safety and monitoring

Long-term AAS use is associated with adverse left ventricular remodeling, persistent lipid abnormalities, and psychiatric sequelae including dependence. Monitoring for anyone exposed to drostanolone should include periodic fasting lipid panels, liver enzymes, hematocrit/hemoglobin, blood pressure, and endocrine evaluation (testosterone, LH, FSH). HPT axis recovery after prolonged use is variable and may require endocrinology referral; some users experience hypogonadism that persists for months after cessation.

Legal status & ethical considerations

Drostanolone is a Schedule III controlled substance in the United States and similarly regulated in many other jurisdictions. It is prohibited in competition and out-of-competition by WADA and most major sports governing bodies. Obtaining it outside a prescription typically involves unregulated sources, introducing risks of adulteration, misdosing, and contamination. Medical providers encountering patients using drostanolone should approach the situation with a harm-reduction framework alongside standard clinical evaluation.

Compound variations

Drostanolone propionate

Masteron

The propionate ester has a short half-life (approximately 1–2 days) and requires more frequent injections than the enanthate form.

Common use case

Shorter duration of exposure and faster clearance compared with longer esters.

Dosage note

Non-medical user reports cite 100–400 mg per week split across multiple injections (e.g., every other day). Not an evidence-based medical dose.

Drostanolone enanthate

Masteron

The enanthate ester is longer-acting than the propionate form and supports once- or twice-weekly injection schedules.

Common use case

Less frequent injections for sustained blood levels; pharmacology is otherwise similar to the propionate ester.

Dosage note

Reported non-medical weekly totals are similar to propionate formulations but given in fewer injections per week.

Dosage and best practices

Dosage principles

  • Historical medical regimens are obsolete and no modern standardized therapeutic dose exists for drostanolone.
  • Non-medical user reports and AAS literature commonly describe drostanolone propionate at 100–400 mg per week (administered as 50–200 mg every other day), and drostanolone enanthate at equivalent weekly totals given once or twice weekly. These figures reflect observed use patterns, not evidence-based medical recommendations.
  • Anyone exposed should obtain baseline and follow-up labs: serum total testosterone, LH, FSH, fasting lipid panel, liver enzymes (AST/ALT), hemoglobin/hematocrit, and blood pressure. Monitoring intervals should be individualized under medical supervision, but AAS monitoring literature commonly references baseline, 4–12 weeks after initiation, and post-cessation assessments.

Best practices

  • Do not use drostanolone outside a licensed prescriber's recommendation. It is not a dietary supplement and carries legal and health risks.
  • If exposure has occurred, establish baseline labs (testosterone, LH/FSH, lipids, liver enzymes, CBC, blood pressure) and repeat them periodically to detect HPT suppression, dyslipidemia, polycythemia, or hepatic injury.
  • Disclose AAS use to healthcare providers — this affects interpretation of laboratory values and clinical management. Prolonged use followed by abrupt cessation may require endocrine follow-up for HPT axis recovery.

Literature and references

Common questions

Is Masteron a dietary supplement?

No. Masteron (drostanolone) is a synthetic anabolic-androgenic steroid, not a dietary supplement. It is a controlled substance in many jurisdictions and requires a licensed prescriber.

Does Masteron cause gynecomastia?

Drostanolone is non-aromatizable and carries a lower risk of estrogen-mediated gynecomastia than aromatizable androgens. However, co-administered drugs or pre-existing hormonal imbalances can still influence individual outcomes.

What medical uses does drostanolone have?

Historical uses included investigation for hormone-responsive advanced breast cancer, but drostanolone is not part of modern standard oncology practice. No current evidence-based medical indications have been established.

How long do effects and side effects last after stopping?

Pharmacologic effects wane as the ester clears (days to about two weeks depending on the ester). Endocrine suppression and adverse lipid changes may persist for weeks to months; HPT axis recovery is variable and sometimes prolonged. Endocrine follow-up is advisable after discontinuation of extended use.

What tests should I get if I have been exposed?

Obtain serum total testosterone, LH, FSH, fasting lipid profile, liver enzymes (AST/ALT), complete blood count (for hematocrit), and blood pressure at baseline and at follow-up intervals. Discuss results with a clinician experienced in endocrine effects of AAS.

Related guides